News
Two major health agencies are facing leadership reshuffles, with the resignations of the FDA’s Vinay Prasad and NICE’s Dr Sam Roberts.
PTC Therapeutics faces pivotal FDA decisions for approvals that could potentially transform their long-term revenues. Click ...
The U.S. Food and Drug Administration's (FDA) top vaccine official is stepping down after just three months in a role that ...
But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...
A biopharmaceutical research company with ties in Andover has laid off a third of its workforce as one of the leaders in gene therapy goes through a “strategic ...
1d
TipRanks on MSNSarepta Stock (SRPT) Rallies on FDA Nod for Broader Gene Therapy UseShares of Sarepta Therapeutics ($SRPT) jumped over 14% on Tuesday after the FDA authorized the company to restart shipments ...
At the 2025 Alzheimer’s Association International Conference, one of the bigger splashes was made by an experimental cardiovascular drug. Newamsterdam Pharma Co. NV presented data showing that its ...
Dr. Vinay Prasad is stepping down as the Food and Drug Administration’s top vaccine regulator after a brief tenure. A ...
George Tidmarsh has only been at the Center for Drug Evaluation and Research for nine days, but will now add supervision of a ...
1d
Amazon S3 on MSNThe story of Sarepta's Duchenne gene therapyThe last couple of weeks has been particularly distressing for Duchenne muscular dystrophy patients and their families. The ...
After our editorial, the agency relents to allow a Duchenne treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results